Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children

BACKGROUND: Typhoid fever caused by multidrug-resistant H58 Salmonella Typhi is an increasing public-health threat in sub-Saharan Africa. We present phase 3 efficacy data from an African trial of a Vi-polysaccharide typhoid conjugate vaccine (Vi-TCV). METHODS: Children aged 9 months to 12 years in B...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Priyanka D., Patel, Pratiksha, Liang, Yuanyuan, Meiring, James E., Misiri, Theresa, Mwakiseghile, Felistas, Tracy, J. Kathleen, Masesa, Clemens, Msuku, Harrison, Banda, David, Mbewe, Maurice, Henrion, Marc, Adetunji, Fiyinfolu, Simiyu, Kenneth, Rotrosen, Elizabeth, Birkhold, Megan, Nampota, Nginache, Nyirenda, Osward M., Kotloff, Karen, Gmeiner, Markus, Dube, Queen, Kawalazira, Gift, Laurens, Matthew B., Heyderman, Robert S., Gordon, Melita A., Neuzil, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202713/
https://www.ncbi.nlm.nih.gov/pubmed/34525285
http://dx.doi.org/10.1056/NEJMoa2035916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202713/
https://www.ncbi.nlm.nih.gov/pubmed/34525285
http://dx.doi.org/10.1056/NEJMoa2035916

Ejemplares similares